Treatment of Thalamocortical Dysrhythmia
OwnerSteven Richard Devore Bestinventor
Life of this patent
Estimating the term…
Abstract
A method for treating conditions associated with thalamocortical dysrhythmia. The method includes applying transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to a patient in need thereof, and administering to the patient a dissociative anesthetic during the TLVES therapy or the TMS therapy. A number of conditions including tinnitus, depression and pain can be treated with TLVES or TMS in combination with the dissociative anesthetic, such as an NMADR inhibitor, including ketamine.
Claims22
A method for treating a condition associated with thalamocortical dysrhythmia, the method comprising in combination:
- applying, external to the skull, transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to a patient suffering from a condition associated with thalamocortical dysrhythmia;
- administering to the patient intravenously, intramuscularly, orally, intranasally or by inhalation a dissociative anesthetic during the TLVES therapy or the TMS therapy.
A method for treating pain, the method comprising in combination,
- applying, external to the skull, transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to an individual having pain;
- administering to the individual intravenously, intramuscularly, orally, intranasally or by inhalation an N-methyl d-aspartate receptor (NMDAR) antagonist during the TLVES therapy or the TMS therapy.
A method for treating depression, comprising in combination:
- applying, external to the skull, transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to a patient suffering from depression;
- administering to the patient intravenously, intramuscularly, orally, intranasally or by inhalation an N-methyl d-aspartate receptor (NMDAR) antagonist during the TLVES therapy or the TMS therapy.
Dependencies are inferred from the claim text.